# An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

> **NCT00420056** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 17 (actual)

## Conditions studied

- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** PD-0332991

## Key facts

- **NCT ID:** NCT00420056
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2010-03
- **Final completion:** 2012-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420056, "An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00420056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*